Pharmacotherapy of mental illness - a historical analysis

@article{Ban2001PharmacotherapyOM,
  title={Pharmacotherapy of mental illness - a historical analysis},
  author={Thomas A. Ban},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2001},
  volume={25},
  pages={709-727}
}
  • T. Ban
  • Published 1 May 2001
  • Psychology, Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
Academic psychiatry and the pharmaceutical industry
  • T. Ban
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2006
Neuropsychopharmacology and the genetics of schizophrenia A history of the diagnosis of schizophrenia
  • T. Ban
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2004
A brief history of antidepressant drug development: from tricyclics to beyond ketamine
TLDR
A historical review of the development of monoaminergic antidepressant drugs and the role of ketamine as the introductory agent of a new era in the research of the neurobiology of depression and how it revealed itself as an exciting option towards obtaining pharmacological agents to treat depression, through the understanding of biological markers.
The history of barbiturates a century after their clinical introduction
TLDR
The problems of safety which, accompanied by the introduction of a range of psychoactive drugs in the 1950s, brought an end to barbiturate use, except in specific applications, such as the induction of anesthesia and the treatment of certain types of epilepsy.
Rapid-acting antidepressants: shared neuropharmacological mechanisms
TLDR
Novel evidence of a specific brain state characterized by slow EEG oscillations and the activation of molecular pathways implicated in rapid-acting antidepressant actions is provided, encouraging the investigation of cortical excitation and the subsequent homeostatic increase of slow EEGscillations as a fundamental basis of rapid- acting antidepressant treatments.
Overcoming Pessimism About Treatment of Addiction
TLDR
This issue of MSJAMA examines misperceptions that have impeded delivery of psychiatric care as scientific research has not been successful in fully convincing the public or physicians that tangible biological disturbances underpin diseases of the mind as well as the body.
Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
TLDR
Aripiprazole is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder and provides a new treatment option with limited adverse effects for patients in need of antipsychotics.
...
...

References

SHOWING 1-10 OF 90 REFERENCES
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
TLDR
In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.
Description and distribution of the subtypes of chronic schizophrenia based on Leonhard's classification.
TLDR
A simplification of the Leonhard scheme is presented, and despite methodological short comings, the similarities in the distribution of subtypes across time and across countries give some support to Leonhard's taxonomy.
Nicotinic Acid and Psychiatry *
  • T. Ban
  • Psychology, Medicine
    Canadian Psychiatric Association journal
  • 1971
TLDR
This paper aims to establish the efficacy of nicotinic acid in the treatment of pellagra, a disease with characteristic neuropsychiatric, dermatological and gastrointestinal manifestations, and subdivide these conditions into two clinical categories: those due to chronic deficiency and Those due to acute deficiency.
The treatment of depressive states with dinitrile succinate.
TLDR
It is concluded that this drug is ineffective in the treatment of depressive states, but this does not exclude the possibility of its efficacy in other conditions.
Biological basis of depression and therapeutic relevance.
  • E. Richelson
  • Psychology, Biology
    The Journal of clinical psychiatry
  • 1991
TLDR
The rich pharmacology for antidepressant drugs involving blockade of neuronal uptake systems for some biogenic amines and blockade of many receptors for neurotransmitters can explain some of their adverse effects and certain interactions with other drugs.
Selective drugs versus heterogeneous diagnoses towards a new methodology in psychopharmacologic research
  • T. Ban
  • Psychology, Medicine
  • 1999
TLDR
It was postulated that a methodology for the delineation of the therapeutic profile of psychotropic drugs and identification of the treatment responsive form(s) of illness is an essential prerequisite for progress in the phannacotherapy of mental illness.
CLINICAL PHARMACOLOGY OF IMIPRAMINE AND RELATED ANTIDEPRESSANT COMPOUNDS.
Our review of the studies of clinical efficacy of the tricyclic compounds in the treatment of depression supports the general view that imipramine and amitriptyline are more effective than placebo,
Efficacy issues with antidepressants.
Clinical trials of antidepressant medications have shown that, overall, these drugs are effective, as measured by a > or = 50% decrease in Hamilton Rating Scale for Depression (HAM-D) total scores in
Psychopharmacology of depression
TLDR
The epidemiology of depressive illness Second generation antidepressants Animal studies on neuropeptides and depressions Testing a proposed model on central serotonergic function and impulsivity Obsessive-compulsive disorder and depression The place of antidepressants in long-term treatment New antidepressants - a look to the future.
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.
TLDR
Clozapine has superior efficacy for treating positive symptoms in partially responsive outpatients with chronic schizophrenia, suggesting that it has utility for a broad spectrum of patients with schizophrenia beyond the most severely ill.
...
...